"I can't even tell you how important this is" — expert reveals why 90% of women don't know they have sleep apnea
Sleep apnea is a condition where your breathing temporarily stops or is disrupted during the night. When you experience this, your brain automatically wakes you from your slumber. You might let out a loud snore, a snort or make a gasping sound in order to breathe again.
In women, snoring can be much less pronounced so it's not as easy to tell from this symptom alone. Women are more likely to experience daytime sleepiness, impaired focus and mood changes.
This can lead to delays in diagnosis as sleep apnea in women can be mistaken for anxiety, depression and menopause. As the signs are more subtle, research suggests as many as 90% of women who have sleep apnea may be unaware they have it.
We've chatted with a sleep medicine specialist and a clinical sleep educator to find out more about this important sleep health topic for women.
What is sleep apnea?
'Sleep apnea is a condition where breathing stops or is disrupted at night time, eroding an individual's quality of sleep,' explains Dr Anthony Izzo, a board-certified neurologist and sleep medicine specialist who is Sleep Center Medical Director at St Vincent Hospital.
'Each time breathing stops, the brain receives an alert about low oxygen, and it's forced from a deep stage of sleep to a light stage to brief wakefulness in order to address the alert.'
There are two main types of sleep apnea: obstructive and central. Obstructive sleep apnea (OSA) is much more common says Dr Izzo.
'OSA occurs because tissues in the top of the airway, behind the nose and mouth, collapse down when the muscles that keep them up relax during sleep as this blocks the flow of air to the lungs,' he explains.
'Central sleep apnea happens when the brain doesn't create the right signal to breath,' he adds.
'It's associated with underlying medical conditions like congestive heart failure, lung diseases, or long-term use of opioid medications. But we don't see much of this in clinical practice.'
Does sleep apnea affect women differently to men?
Yes, it very much does. Women are more likely to experience subtle symptoms such as mood changes and not being able to focus or concentrate well day after day.
This means diagnosis can be delayed or the condition can be mistaken for the symptoms of the menopause or depression.
'I can't even tell you how important this is as sleep apnea in women often goes undiagnosed,' explains Lauri Leadley, clinical sleep educator, president and founder of Valley Sleep Center.
'The symptoms are sometimes attributed to general life challenges such as stress, and the menopause. But the truth is sleep apnea in women is overlooked.'
Symptoms of sleep apnea in women
Although men and women do experience some similar symptoms of sleep apnea, like snoring, there are also differences. Women are more likely to experience these subtle signs.
Frequent morning headaches
If you're prone to starting your mornings with a dull headache, this could be a tell-tale sign. Morning headaches that are present as soon as you wake up are associated with obstructive sleep apnea.
A 2015 study published in the Journal of Headache and Pain looked at 48 people who had been diagnosed with OSA and experienced morning headaches. They found 25% had morning headaches for more than 15 days per month.
Mood changes
Obstructive sleep apnea and its impact on sleep quality can also worsen feeling anxious, irritable and impatient. It can affect your mood and could also lead to depression.
'Sometimes when your symptoms aren't severe, it can be easy to write them off as nothing to worry about,' Lauri explains.
'But my advice is to be mindful about frequent mood swings that regularly leave you feeling anxious or low. No, it is not just you being bitchy or hard to deal with.'
Forgetfulness and fuzzy thinking
Although women with sleep apnea are less likely to experience loud snoring as they suddenly wake during the night, the condition can still disrupt their sleep quality.
Unsurprisingly, this has a knock-on impact on your cognitive health. You may have difficulty thinking clearly, and your attention, focus and concentration can also be impaired.
'Having trouble with focus or memory throughout the day may be the only symptoms a woman with sleep apnea experiences, even though they might not think it's related,' explains Dr Izzo.
Dry mouth in the morning
Regularly waking up with a dry mouth or sore throat can also indicate obstructive sleep apnea. It's regarded as a key symptom in OSA and it's caused by your breathing being impaired throughout the night.
This can lead to a drop in oxygen concentration as a result of open-mouth breathing. Your mouth then becomes dry and you could also be more likely to experience morning headaches too.
Needing to go the toilet more at night
'Frequent urination during the night can also be a sign of sleep apnea in women,' says Lauri.
As OSA causes frequent sleep disruptions, you may find this makes you want to go to the toilet more during the night.
If you find you're waking to urinate several times at night, it could still indicate OSA (even if it seems like a separate and unrelated issue).
What causes sleep apnea in women?
Some of the causes of OSA are similar for both men and women. For example, weight gain and the shape or anatomy of the upper airway. With central sleep apnea, it's often associated with underlying medical conditions such as congestive heart failure and lung diseases.
We also see sleep apnea worsen during menopause
Hormonal changes can play a key role in the onset of sleep apnea in women as Dr Izzo explains.
'We know that sleep apnea typically can happen in patients without a prior history, starting in the second trimester of pregnancy. It can worsen in severity throughout the second and third trimesters,' he says.
'We also see sleep apnea worsen during menopause, although typically patients will have already been diagnosed pre-menopause in this situation,' he adds. 'Menopause is often associated with weight gain, which in turn, worsens sleep apnea severity.'
How women can treat sleep apnea
While the symptoms of sleep apnea may present differently, the solutions remain largely the same. But it's different for everyone, so be sure to speak directly with a physician. Below are common treatments for sleep apnea.
Lifestyle changes
For mild sleep apnea, lifestyle changes, such as quitting smoking and losing weight and improving sleep hygiene can be very beneficial in treating the condition.
If you also have allergies which affect your breathing such as allergic rhinitis, your physician or sleep specialist could suggest a treatment that could help to mitigate your allergy symptoms.
Keeping regularly active is good for your lungs as well as your general health and could help to reduce the number of breathing pauses you experience while you sleep.
CPAP mask
If lifestyle changes don't fully help to treat your sleep apnea symptoms, you may be provided with a continuous positive airway pressure (CPAP) machine and mask.
'A CPAP mask is considered first line for sleep apnea as it's effective for all severities of OSA,' says Dr Izzo.
The machine works by delivering air at pressure through a mask that is placed over your nose and mouth. It can help to keep your airways open to prevent impaired breathing while you sleep.
Mouthguard
Another treatment alternative for mild to moderate sleep apnea is an oral device such as a sleep apnea mouthguard that you would wear at bedtime. These are designed to keep your throat open while you sleep to lessen symptoms.
They work by preventing your tongue from blocking your throat and this can help to prevent snoring. Another option is a mouthguard that works slightly differently by moving your lower jaw forward to keep your throat open.
These oral devices are easier to use but you may not find them comfortable, and they may not work for everyone.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Study reveals this type of exercise lowers your biological age by 9 years
When you buy through links on our articles, Future and its syndication partners may earn a commission. If you're looking to pause time, we've got good news — when it comes to biological aging, that's the aging process that happens inside your cells, sweating can help. Specifically, sweating due to high-impact exercise, which can lower your biological age by nearly a decade, according to researchers. The study, conducted at Brigham Young University and published in the Preventive Medicine medical journal, looked at the data of more than 5,800 adults aged 20-84. The study looked at the participants' biological age by examining the length of their telomeres — these are the protective DNA caps at the end of chromosomes. Telomeres prevent your DNA from getting damaged; they shorten as we get older, and shortened telomeres are often associated with age-related diseases. The measurement is taken through blood samples. The researchers found that people who consistently performed high levels of physical activity, specifically high-impact activity, had longer telomeres than those with sedentary lifestyles. For the study, to be highly active, women had to engage in 30 minutes of jogging per day and 40 minutes for men, five days a week. They concluded that regular high-impact exercise added nine years of reduced cellular aging. 'If you want to see a real difference in slowing your biological aging, it appears that a little exercise won't cut it,' exercise science professor Larry Tucker said. 'You have to work out regularly at high levels.' If you're new to jogging, it can be difficult to know where to start. Mixing jogging with walking intervals as you get fitter and build up your distance, also known as Jeffing, can be beneficial. Here's everything you need to know about Jeffing, and a round-up of the best running shoes on the market. That said, if you're not a runner or you're worried about the impact of running on your joints, high-intensity training doesn't have to involve pounding the sidewalk or hours on the treadmill. HIIT training, cycling sprints on a stationary bike, taking a spin class, or using the rowing machine in the gym all count as high-intensity exercise. Find the one that works for you, and you'll increase your cardiovascular fitness while lowering your biological age. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget running and swimming — study finds this sport adds 10 years to your life Forget gym machines — study shows this type of exercise is the most effective at building strength, muscle and power Forget 10,000 steps — study reveals the real number of minimum daily steps you should take, according to your age
Yahoo
35 minutes ago
- Yahoo
RHOC's Emily Simpson Gives Update on Son Luke's Eating Disorder
revealed a worrying issue regarding her son Luke during the Season 19 premiere. At the time of filming, the 10-year-old was newly diagnosed with Avoidant/Restrictive Food Intake Disorder, or ARFID. Emily was understandably distraught. But now, armed with knowledge and the help of specialists, the RHOC star is getting a handle on how to manage Luke's diagnosis. She's been met with tremendous support from fans and the online community as well. How RHOC star Emily Simpson's son Luke is managing his food issues 'Luke is doing much better than when we were filming,' Emily exclusively told E! News. 'That was a huge stress for him and also he's not in school, which was another big stress for him.' She continued, 'He has some ADHD and OCD. He has a very severe separation anxiety when it comes to me and we've worked really hard to alleviate that. He's much more comfortable with me going leaving and coming home now.' The RHOC veteran, and husband Shane Simpson, learned to avoid pressuring their son to eat more, on the advice of specialists. Right now, Luke will 'only eat three to four different things.' 'Before I understood the disorder and what was actually happening in his brain, we would get frustrated with him that he wouldn't try different foods,' Emily explained. 'I made a lot of mistakes along the way. Now we know that he has safe foods and we always have those in the house. We don't give him any grief about eating those safe foods that he's comfortable with and we try to introduce, every once in a while, something new.' 'We sent him to a specialist and we try to get as many answers as we can in regards to that. He does a lot of testing. There are many more conversations,' Emily concluded. Catch Real Housewives of Orange County Thursdays at 9/8c on Bravo. It streams on Hayu in the UK and Ireland. TELL US – WHAT IS YOUR REACTION TO EMILY'S UPDATE? The post RHOC's Emily Simpson Gives Update on Son Luke's Eating Disorder appeared first on Reality Tea.